Baseline characteristics of the eligible patients
Characteristics . | Chlorambucil (n = 100) . | Fludarabine (n = 93) . |
---|---|---|
Age (y) | 70 (65-78) | 71 (65-78) |
Age group, % | ||
65-69 y | 47 | 45 |
70-74 y | 31 | 33 |
75-79 y | 22 | 22 |
Binet stage, % | ||
A | 16 | 13 |
B | 44 | 51 |
C | 40 | 36 |
Rai stage, % | ||
0: low risk | 5 | 5 |
I or II: intermediate risk | 52 | 55 |
III or IV: high risk | 43 | 40 |
Male sex, % | 63 | 66 |
Median time from initial diagnosis to study entry (mo) | 11 (0-110) | 17 (0-92) |
ECOG performance status, % | ||
0 | 42 | 46 |
1 | 49 | 52 |
2 | 9 | 2 |
Concomitant disease, % | ||
None | 33 | 35 |
1 | 35 | 32 |
2 or more | 32 | 33 |
Thymidine kinase (U/L) | 20 (3-108) | 18 (4-71) |
β2 microglobulin (mg/L) | 4 (2-8) | 4 (2-7) |
Patients with del(17p), n (%) | 5 (6) | 5 (7) |
Patients with del(11q), n (%) | 8 (10) | 14 (19) |
Patients with 12q+, n (%) | 17 (20) | 16 (25) |
Patients with unmutated IgVH (%) | 27 (59) | 28 (67) |
Characteristics . | Chlorambucil (n = 100) . | Fludarabine (n = 93) . |
---|---|---|
Age (y) | 70 (65-78) | 71 (65-78) |
Age group, % | ||
65-69 y | 47 | 45 |
70-74 y | 31 | 33 |
75-79 y | 22 | 22 |
Binet stage, % | ||
A | 16 | 13 |
B | 44 | 51 |
C | 40 | 36 |
Rai stage, % | ||
0: low risk | 5 | 5 |
I or II: intermediate risk | 52 | 55 |
III or IV: high risk | 43 | 40 |
Male sex, % | 63 | 66 |
Median time from initial diagnosis to study entry (mo) | 11 (0-110) | 17 (0-92) |
ECOG performance status, % | ||
0 | 42 | 46 |
1 | 49 | 52 |
2 | 9 | 2 |
Concomitant disease, % | ||
None | 33 | 35 |
1 | 35 | 32 |
2 or more | 32 | 33 |
Thymidine kinase (U/L) | 20 (3-108) | 18 (4-71) |
β2 microglobulin (mg/L) | 4 (2-8) | 4 (2-7) |
Patients with del(17p), n (%) | 5 (6) | 5 (7) |
Patients with del(11q), n (%) | 8 (10) | 14 (19) |
Patients with 12q+, n (%) | 17 (20) | 16 (25) |
Patients with unmutated IgVH (%) | 27 (59) | 28 (67) |
Median values are given for continuous variables (5th to 95th percentiles); percentages are given for categorical values.
ECOG indicates Eastern Cooperative Oncology Group.